Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.79 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.79 |
| ▸ | CYP8B1 | Q9UNU6 | 3/20 | 0.79 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.79 |
| ▸ | TACR1 | P25103 | 1/20 | 0.79 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.79 |
| ▸ | CCR4 | P51679 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itraconzole SCHEMBL1650334 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL17739437 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL10073778 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL65702 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL65701 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL2615053 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL12887924 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Itraconzole SCHEMBL4149722 | 1.00 | CYP3A4 (0.79) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL28021428 | 0.99 | CYP3A4 (0.78) | CYP3A4ABCG2LMNAMAPTABCB11 | |
| Saperconazole SCHEMBL28133394 | 0.99 | CYP3A4 (0.78) | CYP3A4ABCG2LMNAMAPTABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346998-B1 | TOPICAL FILM DELIVERY SYSTEM | SIDMAK LABORATORIES INDIA PVT LTD (IN) | 2025-04-16 | — | — | EP | claimed |
| US-20260048049-A1 | METHODS FOR TREATING CANCER USING INHALED ANGIOGENESIS INHIBITOR | PULMATRIX OPERATING CO INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250221928-A1 | ANTIFUNGAL DRY POWDERS | PULMATRIX OPERATING CO INC (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4580603-A2 | SOFT CHEWABLE FORMULATIONS WITH ACTIVE INGREDIENTS | Noble Pharma, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-12285522-B2 | Thermally gelling drug formulations | UNM RAINFOREST INNOVATIONS (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250114411-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | EVELO BIOSCIENCES INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268718-B2 | Control of cellular redox levels | LABYRINTH HOLDINGS LLC | 2025-04-08 | — | — | US | disclosed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-20230355523-A1 | SELF-EMULSIFYING NANO-EMULSIONS | MEDPHARM HOLDINGS LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355689-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | EVELO BIOSCIENCES, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4236919-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | Merck Patent GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-11628162-B2 | Methods of treating cancer with an FGFR inhibitor | INCYTE CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| WO-2023049268-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | EVELO BIOSCIENCES, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230052945-A1 | Thermally Gelling Drug Formulations | UNM RAINFOREST INNOVATIONS (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4081195-A1 | SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES | Evelo Biosciences, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-11464736-B2 | Thermally gelling drug formulations | UNM RAINFOREST INNOVATIONS (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022090296-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR ENHANCING SOLUBILITY OF POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048049-A1 | METHODS FOR TREATING CANCER USING INHALED ANGIOGENESIS INHIBITOR | VEGFA, EGFR, KDR | CYP3A4 3178/4885ABCG2 2689/4885LMNA 3574/4885 |
| US-11628162-B2 | Methods of treating cancer with an FGFR inhibitor | FGFR2, FGFR3, FGFR1 | CYP3A4 4829/4885ABCG2 2048/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.